Pacira BioSciences, Inc. PCRX Ratios & Valuation
| TTM Q1 '26 | TTM Q4 '25 | TTM Q3 '25 | TTM Q2 '25 | TTM Q1 '25 | ||
|---|---|---|---|---|---|---|
| Profitability | ||||||
| Gross margin | 79.3%+1.7pp | 79.4%+3.7pp | 79.2%+4.8pp | 78.2%+4.1pp | 77.6%+4.5pp | |
| Free cash flow margin | 18.1%-4.6pp | 18.8%-6.7pp | 17.3%-10.5pp | 16.6%-10.2pp | 22.7%-2.7pp | |
| Efficiency | ||||||
| Asset turnover | 0.5×+0.1× | 0.5×+0.1× | 0.5×+0.1× | 0.4×0.0× | 0.4×0.0× | |
| Inventory turnover | 1.1×-0.3× | 1.1×-0.4× | 1.1×-0.6× | 1.2×-0.6× | 1.4×-0.6× | |
| Liquidity | ||||||
| Current ratio | 4.7×+2.3× | 4.5×+2.1× | 5.3×+3.0× | 2.4×-4.4× | 2.4×-3.4× | |
| Quick ratio | 3.4×+1.4× | 3.3×+1.3× | 3.8×+1.9× | 1.9×-3.8× | 2×-2.8× | |
| Cash ratio | 1.3×+0.4× | 1.3×+0.4× | 1.4×+0.6× | 1×-1.7× | 0.9×-1.1× | |
| Leverage | ||||||
| Debt-to-equity | 0.6×+0.2× | 0.6×-0.1× | 0.6×+0.1× | 0.5×+0.3× | 0.4×+0.2× | |
| Debt-to-assets | 0.3×+0.1× | 0.3×0.0× | 0.3×+0.1× | 0.2×+0.1× | 0.2×+0.1× | |
| Per Share | ||||||
| Book value per share | $15.98-6.9% | $15.39-8.6% | $16.36+0.7% | $16.67-4.2% | $17.16+0.4% | |
| Valuation | ||||||
| Market capitalization | $942.78M-14.5% | $1.11B+28.0% | $1.16B+66.6% | $1.14B-14.3% | $1.15B-15.4% | |
| Enterprise value | $1.21B+2.6% | $1.37B+18.9% | $1.44B+76.3% | $1.19B-4.9% | $1.22B-9.9% | |
| Price / sales | 1.3×-0.3× | 1.5×+0.3× | 1.6×+0.6× | 1.6×-0.3× | 1.6×-0.4× | |
| Price / book | 1.5×+0.1× | 1.6×+0.5× | 1.6×+0.7× | 1.5×0.0× | 1.4×-0.1× | |
| EV / sales | 1.7×0.0× | 1.9×+0.2× | 2×+0.8× | 1.7×-0.1× | 1.7×-0.3× | |
| Free cash flow yield | 13.8%-0.4pp | 12.3%-8.3pp | 10.7%-17.1pp | 10.3%-3.6pp | 13.9%+1.1pp |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- What are Pacira BioSciences, Inc.'s profit margins?
- Pacira BioSciences, Inc. (PCRX) runs a 79.3% gross margin and a 3.3% operating margin, with a 0.7% net margin.
- Where do Pacira BioSciences, Inc.'s ratios come from?
- Every ratio is computed from Pacira BioSciences, Inc.'s SEC filings — trailing-twelve-month flows over period-end balances. Valuation multiples combine those fundamentals with market data, recomputed each period. Switch between quarterly, annual, and TTM, or open any ratio for its full history and peer comparisons.
